ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,040.53
-0.50%
Dow Jones
44,544.66
-0.75%
US Dollar vs MXN
21.1092
3.05%
Brent Oil
76.535
0.24%
Bitcoin
94,121.97
-3.67%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX

  6. AEON Biopharma Inc (AEON) Cotización

AEON Biopharma Inc

AEON Biopharma Inc (AEON)

AMEX
0.1287
0.0072
(5.93%)
Cerrado 03 Febrero 3:00PM
Delayed by 15 minutes
0.1232
-0.0055
(-4.27%)
Fuera de horario: 6:59PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
0.1232
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
7,659,286
0.1211 Rango del Día 0.1441
0.1013 Rango de 52 semanas 17.17
Capitalización de Mercado [m]
4.924M
Precio Anterior
0.1215
Precio de Apertura
0.1211
Hora
33671
@
0.1287
Última hora de negociación
Volumen financiero
US$ 995,460
Precio Promedio Ponderado
0.129968
Volumen promedio (3 m)
17,961,501
Acciones en circulación
39,970,693
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
0.20
Beneficio por acción (BPA)
0.6
turnover
52.75M
Beneficio neto
24.05M

Acerca de AEON Biopharma Inc

AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-... AEON Biopharma, Inc. is a bio-pharmaceutical company. The Company is focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets. ABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium clostridium botulinum. The active part of the botulinum toxin is the 150 kDa component, and the remaining 750 kDa of the complex is made up of accessory proteins. When injected at therapeutic levels, ABP-450 blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle. It is also engaged in the Phase II clinical study of ABP-450 for the treatment of cervical dystonia. Cervical dystonia, also known as spasmodic torticollis, is a neurological condition. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Blank Checks
Sede
Wilmington, Delaware, USA
Fundado
2022
AEON Biopharma Inc is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker AEON. The last closing price for AEON Biopharma was US$0.12. Over the last year, AEON Biopharma shares have traded in a share price range of US$ 0.1013 to US$ 17.17.

AEON Biopharma currently has 39,970,693 shares in issue. The market capitalisation of AEON Biopharma is US$4.86 million. AEON Biopharma has a price to earnings ratio (PE ratio) of 0.20.

AEON Últimas noticias

Más noticias

Form DEF 14A - Other definitive proxy statements

23 Enero 2025
Edgar (US Regulatory)

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

13 Enero 2025
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

07 Enero 2025
Edgar (US Regulatory)

Form 8-K - Current report

06 Enero 2025
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

06 Enero 2025
Edgar (US Regulatory)

Form 8-K - Current report

20 Diciembre 2024
Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

14 Noviembre 2024
Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]

13 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

13 Noviembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 Octubre 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.0106-7.922272047830.13380.15310.11558732150.13226657CS
4-0.4363-77.98033958890.55950.590.1013565399390.17342235CS
12-0.6868-84.79012345680.810.90.1013179615010.17785108CS
26-1.7868-93.54973821991.911.980.101378473810.18772753CS
52-6.9968-98.26966292137.1217.170.101343650040.44878994CS
156-10.0168-98.785009861910.1417.170.101328778540.49160612CS
260-10.0168-98.785009861910.1417.170.101328778540.49160612CS

AEON - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de AEON Biopharma?
El precio actual de las acciones de AEON Biopharma es US$ 0.1232
¿Cuántas acciones de AEON Biopharma están en circulación?
AEON Biopharma tiene 39,970,693 acciones en circulación
¿Cuál es la capitalización de mercado de AEON Biopharma?
La capitalización de mercado de AEON Biopharma es USD 4.86M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de AEON Biopharma?
AEON Biopharma ha negociado en un rango de US$ 0.1013 a US$ 17.17 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de AEON Biopharma?
El ratio precio/beneficio de AEON Biopharma es 0.2
¿Cuál es el ratio de efectivo a ventas de AEON Biopharma?
El ratio de efectivo a ventas de AEON Biopharma es 0.09
¿Cuál es la moneda de reporte de AEON Biopharma?
AEON Biopharma presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de AEON Biopharma?
El último ingresos anual de AEON Biopharma es USD 52.75M
¿Cuál es el último beneficio anual de AEON Biopharma?
El último beneficio anual de AEON Biopharma es USD 24.05M
¿Cuál es la dirección registrada de AEON Biopharma?
La dirección registrada de AEON Biopharma es CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801
¿En qué sector industrial opera AEON Biopharma?
AEON Biopharma opera en el sector BLANK CHECKS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
DXFEason Technology Limited
US$ 26.00
(57.29%)
895.37k
SGNSigning Day Sports Inc
US$ 3.73
(45.70%)
56.03M
CLDICalidi Biotherapeutics Inc
US$ 0.7629
(21.95%)
7.23M
XTNTXtant Medical Holdings Inc
US$ 0.6149
(15.50%)
99.67k
NNVCNanoViricides Inc
US$ 1.185
(10.75%)
684.82k
EXODExodus Movement Inc
US$ 50.00
(-18.54%)
155.49k
SENSSenseonics Holdings Inc
US$ 0.9609
(-11.84%)
17.03M
CPHIChina Pharma Holdings Inc
US$ 0.2183
(-9.91%)
325.86k
GOROGold Resource Corporation
US$ 0.3462
(-9.56%)
1.49M
EONREON Resources Inc
US$ 0.82
(-9.50%)
1.63M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 27.02
(-0.48%)
102.26M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
US$ 5.82
(1.39%)
81.08M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
US$ 2.3017
(-2.26%)
75.06M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF
US$ 3.565
(7.70%)
70.47M
SOXSDirexion Daily Semiconductor Bear 3X Shares New
US$ 20.61
(0.73%)
67.19M

AEON Discussion

Ver más
tw0122 tw0122 3 semanas hace
All out at .19 good luck nice bottoming 
👍️0
glenn1919 glenn1919 3 semanas hace
AEON.......................................@.20 .........................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783







............thx.......................
👍️0
tw0122 tw0122 3 semanas hace
Bounce bounce break .14 see .20
At .13
👍️0
Backstabbed Backstabbed 3 semanas hace
$AEON - 2 filings released AH! SC-13G
👍️0
0210 0210 4 semanas hace
93m shs traded = 50m buys + 8m(?) vs. 35m sells: https://ih.advfn.com/stock-market/AMEX/aeon-biopharma-AEON/trades
👍️0
0210 0210 4 semanas hace
new lows still, hah! hmmm.....interesting AEON teens & twenties.
👍️0
0210 0210 4 semanas hace
aeon aeON AEON https://www.benzinga.com/news/25/01/42821213/why-aeon-biopharma-stock-is-down-65-today
👍️0
0210 0210 4 semanas hace
A/S 500m O/S 40m Float 10m. 70m traded so far today. buys > sells. hmmm....
👍️0
0210 0210 4 semanas hace
AEON 19-20cents way below all-time VWAPs and 50cents $20m new offering price!? hmmm....chap 11 pps? lolol.
👍️0
ErnieBilco ErnieBilco 4 semanas hace
Offering meltdown TIME TO BUY
👍️0
glenn1919 glenn1919 4 meses hace
AEON............................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 5 meses hace
AEON new 52=week low
👍️0
willlbone willlbone 6 meses hace
Dilution.
👍️0
glenn1919 glenn1919 6 meses hace
AEON.......................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 6 meses hace
AEON under $3
👍️0
glenn1919 glenn1919 7 meses hace
AEON..............................................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
👍️0
DewDiligence DewDiligence 7 meses hace
AEON repositions ABP-450 as_a potential Botox biosimilar:

https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000126.html

AEON is nearly insolvent (#msg-174417740), so it’s hard to see how they complete a phase-3 trial to obtain FDA approval using the 351(k) pathway.

This looks like another instance of Zebra’s Law.

Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
👍️0
Monksdream Monksdream 7 meses hace
AEON new 52 week low
👍️0
Monksdream Monksdream 7 meses hace
AEON new 52 week low
👍️0
DewDiligence DewDiligence 8 meses hace
AEON—>55% workforce reduction—ABP-450 clinical development suspended:

https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000294.html Upon securing additional capital, we would be positioned to announce a revised clinical development strategy for our pipeline of ABP-450 programs. AEON is all but insolvent—see #msg-174417740.

Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
👍️0
DewDiligence DewDiligence 9 meses hace
AEON has a liquidity problem—1Q24 results:

https://www.globenewswire.com/news-release/2024/05/14/2881873/0/en/AEON-Biopharma-Reports-First-Quarter-2024-Financial-Results.html

Net current assets at 3/31/24 were negative ($13.5M). Hence, even after accounting for the $15.0M AEON received from its supplier, Daewoong in an Apr 2024 private placement, net current assets as of today are either close to zero or negative.

No CC.
👍️0
DewDiligence DewDiligence 9 meses hace
AEON plows on despite setbacks:

https://www.globenewswire.com/news-release/2024/05/09/2878729/0/en/AEON-Biopharma-Provides-Update-on-Development-Pipeline.html
👍️0
Monksdream Monksdream 9 meses hace
AEON new 52+ week low
👍️0
DewDiligence DewDiligence 9 meses hace
AEON—(-53%)—reports failed phase-2 in migraine prevention:

https://finance.yahoo.com/news/aeon-biopharma-announces-preliminary-top-110000987.html AEON Biopharma…today announced that the preliminary top-line results from its planned interim analysis of the Phase 2 trial with ABP-450 in the preventive treatment for chronic migraine did not meet the primary endpoint. This is AEON’s second phase-2 failure in migraine, having whiffed in a prior phase-2 for treatment (rather than prevention) of episodic migraine (#msg-173058579).

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau, sourced from Korea's Daewoong.

AEON’s lead indication had previously been cervical dystonia, but AEON backed off from CD after RVNC reported stellar data in that indication.

Please see #msg-172274907 for related info.
👍️0
DewDiligence DewDiligence 10 meses hace
Dilution from the redemption of warrants:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001837607/000183760724000017/aeon-20240329x8k.htm
👍️0
trglaa trglaa 10 meses hace
What happened here today?
👍️0
DewDiligence DewDiligence 10 meses hace
AEON 4Q23 financials:

https://www.globenewswire.com/news-release/2024/03/29/2854830/0/en/AEON-Biopharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
👍️0
DewDiligence DewDiligence 11 meses hace
AEON updates plans for migraine program:

https://finance.yahoo.com/news/aeon-biopharma-announces-clinical-productive-203000664.html
👍️0
DewDiligence DewDiligence 11 meses hace
AEON sells $15M of convertible debt to_supplier, Daewoong:

https://finance.yahoo.com/news/aeon-biopharma-announces-15-million-202900910.html
👍️0
DewDiligence DewDiligence 1 año hace
AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-clinical-210500488.html

CD had been AEON’s lead indication for ABP-450, but AEON changed gears and made episodic migraine the lead indication after RVNC reported Daxxify data in CD (https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm ). When AEON’s phase-2 in episodic migraine failed in Oct 2023 (#msg-173058579), CD again became the lead indication by default.

The above PR also includes preclinical data for ABP-450 in PTSD (!?).

AEON needs to raise a significant amount of cash to conduct a phase-3 trial in any indication (#msg-173211412).

Reminder: ABP-450, sourced from Korea’s Daewoong, is the exact same toxin as EOLS’ Jeuveau. See #msg-172274907 for background info.
👍️0
DewDiligence DewDiligence 1 año hace
AEON needs to raise cash very soon:

https://www.globenewswire.com/news-release/2023/11/13/2779046/0/en/AEON-Biopharma-Reports-Third-Quarter-2023-Financial-Results.html The Company reported cash, cash equivalents and investments were approximately $16.2 million as of September 30, 2023.

The Company believes its cash, cash equivalents and investments will be sufficient to fund its planned clinical studies, as well as support corporate operations into mid-December 2023. No quarterly CC.
👍️0
DewDiligence DewDiligence 1 año hace
AEON phase-2 trial_in episodic migraine misses_ primary_endpoint:

https://finance.yahoo.com/news/aeon-biopharma-announces-topline-results-200500504.html On the primary endpoint, the topline data showed ABP-450 had a treatment effect with mean reductions in MMD [monthly migraine days] of 4.8 days at the 150U dose (n = 99) and 5.0 days at the 195U dose (n = 108), compared to only 4.2 days in placebo (n = 98) at weeks 21-24, but did not meet statistical significance… Episodic migraine is (was) ABP-450’s lead indication. The lead indication had previously been cervical dystonia, but AEON backed off from CD due, presumably, to RVNC’s stellar dataset in that indication.

AEON’s ABP-450 is the exact same drug as EOLS’ Jeuveau. Please see #msg-172274907 for related info.
👍️0
DewDiligence DewDiligence 1 año hace
AEON's trading liquidity is so low it doesn't take much to move the share price. Today's news was actually minor in the overall scheme of things insofar as AEON has apparently put the brakes on its clinical program in cervical dystonia in order to pursue episodic migraine.
👍️0
trglaa trglaa 1 año hace
Nice run today.
👍️0
DewDiligence DewDiligence 1 año hace
AEON presents phase-2 data in cervical dystonia:

https://finance.yahoo.com/news/aeon-biopharma-presents-positive-results-120000687.html

Note: Episodic migraine, rather than cervical dystonia, is now AEON’s lead indication for ABP-450. This change is presumably due to RVNC’s robust data in cervical dystonia and the recent FDA approval of Daxxify for CD.

See #msg-172274963 for related info.
👍️0
DewDiligence DewDiligence 2 años hace
AEON's initial press release:

https://finance.yahoo.com/news/aeon-biopharma-announces-closing-business-110000037.html
👍️0
TESLA777 TESLA777 2 años hace
$AEON This is the one Im watching/trading tomorrow....GLTY......
👍️0
DewDiligence DewDiligence 2 años hace
AEON’s corporate slide presentation:

https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm

Notably, AEON’s lead indication is now episodic migraine. AEON’s lead indication was previously cervical dystonia, so it seems reasonable to surmise that RVNC’s stellar data in CD altered AEON’s plans.
👍️0
DewDiligence DewDiligence 2 años hace
AEON seeks_to_compete_in_the therapeutic—(rather than aesthetic)—market_for botulinum toxin. AEON's botulinum toxin, ABP-450 is the exact same product as EOLS’ Jeuveau, sourced from Korea's Daewoong.
👍️0
DewDiligence DewDiligence 2 años hace
AEON Biopharma begins_trading_7/24/23_under_the_symbol, AEON, following the closing of the SPAC merger with PMGM:

https://finance.yahoo.com/news/priveterra-acquisition-corp-announces-completion-202700149.html
👍️0

Su Consulta Reciente

AMEX
AEON
AEON Biopharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios